story of the week
Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Ann. Oncol 2024 Jun 26;[EPub Ahead of Print], E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, R Califano, SM Gadgeel, JC Yang, S Yamamoto, K Azuma, YJ Kim, KH Lee, P Danchaivijitr, CG Ferreira, Y Cheng, MAN Sendur, GC Chang, CC Wang, K Prabhash, Y Shinno, D Stroyakovskiy, L Paz-Ares, JR Rodriguez-Cid, C Martin, MRG Campelo, H Hayashi, D Nguyen, P Tomasini, M Gottfried, C Dooms, A Passaro, M Schuler, ACZ Gelatti, S Owen, K Perdrizet, SI Ou, JC Curtin, J Zhang, M Gormley, T Sun, A Panchal, M Ennis, E Fennema, M Daksh, S Sethi, JM Bauml, SH LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.